Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Atrial Fibrillation
Interventions
DRUG

Brinavess (Vernakalant)

3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes

DRUG

Corvert (Ibutilide)

Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.

Trial Locations (1)

A-1090

Medical University of Vienna, Department of Emergency Medicine, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01447862 - Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation | Biotech Hunter | Biotech Hunter